Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2010:2010:206801.
doi: 10.1155/2010/206801. Epub 2010 Jun 27.

Failed Switching off in the MIBI-Parathyroid Scintigraphy in a Dialyzed Patient with Secondary Hyperparathyroidism Responsive to Cinacalcet Therapy

Piergiorgio Bolasco  1 , Alessandra Serra, Maurizio Loi, Andrea Galfré, Mario Piga
Affiliations
Case Reports

Failed Switching off in the MIBI-Parathyroid Scintigraphy in a Dialyzed Patient with Secondary Hyperparathyroidism Responsive to Cinacalcet Therapy

Piergiorgio Bolasco et al. Int J Endocrinol. 2010.

Abstract

The aims of your case report is to show the predictivity of (99m)Tc-sestamibi (MIBI) scintigraphy and doppler ultrasound imaging on secondary hyperparathyroidism (SHPT) in a patient responsive to calcimimetic treatment. Moreover, it has been reported that calcimimetic has great potential in reducing the volume of the parathyroid gland. On the other hand, the MIBI scintigraphy is considered a crucial diagnostic procedure to monitor the response to therapy in terms of turnover and cellular metabolism; whereas, ultrasound to monitor the volume variation in response to treatment. It is described the case of a 73-year-old man on hemodialysis from 1995 for ESRD. Within 2 years the patient gradually developed SHPT with progressively increased iPTH up to 1,000 rhog/ml. The ultrasound, highlighted the presence of two parathyroid hyperplasia, confirmed by scintigraphy, showing focal increase uptake of sestamibi in the same anatomical areas. As a result of the patient's refusal to perform a parathyroidectomy, cinacalcet, was administered (65 mg overage daily dose). After a year of treatment, there was a striking decrease of iPTH (from 1300 to 57 rhog/ml, -95%); but, on the contrary to expectations, this positive metabolic outcome, was not followed by parathyroid changes in ultrasound and scintigraphic findings.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Figure 2
Figure 2
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Sprague SM, Coyne D. Control of secondary hyperparathyroidism by vitamin D receptor agonists in chronic kidney disease. Clinical Journal of the American Society of Nephrology. 2010;5(3):512–518. - PubMed
    1. Bover J, Aguilar A, Baas JP, et al. Calcimimetics in the chronic kidney disease-mineral and bone disorder. International Journal of Artificial Organs. 2009;32(2):108–121. - PubMed
    1. Fuster D, Ybarra J, Torregrosa JV, et al. Double-phase parathyroid 99mTc-sestamibi scintigraphy in chronic haemodialysis patients: correlation with biochemical markers of parathyroid function. Nuclear Medicine Communications. 2003;24(1):85–90. - PubMed
    1. Gotway MB, Reddy GP, Webb WR, Morita ET, Clark OH, Higgins CB. Comparison between MR imaging and 99mTc MIBI scintigraphy in the evaluation of recurrent or persistent hyperparathyroidism. Radiology. 2001;218(3):783–790. - PubMed
    1. Olaizola I, Zingraff J, Heuguerot C, et al. [(99m)Tc]-sestamibi parathyroid scintigraphy in chronic haemodialysis patients: static and dynamic explorations. Nephrology Dialysis Transplantation. 2000;15(8):1201–1206. - PubMed

Publication types